Controls ASD P-value WBC (109/L) 6.91 ± 0.42 7.96 ± 0.37 0.070 Neu [109/L (%)] 3.38 ± 0.34 (47.4 ± 1.8 %) 3.91 ± 0.36 (48.1 ± 3.2 %) 0.117 Lym [109/L (%)] 2.75 ± 0.12 (41.2 ± 1.8 %) 3.07 ± 0.26 (39.2 ± 3.2 %) 0.283 Mon [109/L (%)] 0.49 ± 0.03 (7.2 ± 0.4 %)…
Total <30 years 30–49 years ≥50 years Characteristics (n = 111) (n = 14) (n = 45) (n = 52) n(%) n(%) n(%) n(%) p-value Gender Men 43(38.7) 5(35.7) 20(44.4) 18(34.6) 0.593a Women 68(61.3) 9(64.3) 25(55.6) 34(65.4) Smoking history…
Four-step-protocol Six-step-protocol Pat 1 Pat 2 Pat 3 Pat 4 Pat 5 Pat 6 Pat 7 Pat 8 Gender f f f f f m f f Age (years)…
n = 214 n % Gender Women 113 53.1 Men 100 46.9 Age (year) 24 and below 6 2.8 25–44 25 11.8 45–64 72 34.1 65–84 97 46.0 85 and above…
n % Mean ± SD Chi2 Q1–Q3 p Gender Women 123 46.8 1.1 Men 140 53.2 0.29 Age 24 and below 4 1.5 25–44 20 7.6 60.2 ± 13.2 298.7 45–64 151 57.6…
Variable Rehabilitation group Control group Before PR After PR p-value Before observation After observation p-value MRC 1.3 ± 1.1 0.6 ± 0.5 0.047 1.4 ± 0.9 1.8 ± 1.3 0.313 OCD 2.0 ± 0.8 2.3 ± 0.9 0.375 1.6 ± 1.4 1.6 ± 1.3 0.999 FI…
Characteristics All respondents 50+ IUHP 50–59 IUHP 60+ IUHP 2005 IUHP 2007 IUHP 2012 n = 323 n = 217 n = 106 n = 56 n = 96 n = 171 % (CI) % (CI) % (CI) % (CI) % (CI)…
Dubinska-Magiera M, Zaremba-Czogalla M, Rzepecki R (2013) Muscle development, regeneration and laminopathies: how lamins or lamina-associated proteins can contribute to muscle development, regeneration and disease. Cell Mol Life Sci 70(15):2713–2741PubMedCentralPubMedCrossRef…
© Springer International Publishing Switzerland 2015Mieczyslaw Pokorski (ed.)Respiratory HealthAdvances in Experimental Medicine and Biology86110.1007/5584_2015_143 Ondine’s Curse – Genetic and Iatrogenic Central Hypoventilation as Diagnostic Options in Forensic Medicine Robert Susło1, 2 , Jakub Trnka1, Jacek Siewiera1, 3…
1 A clear title, with “Urgent field safety notice” followed by the commercial name of the affected product, an FSCA-identifier (e.g., date) and the type of action. 2 Specific details…
